Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

Peregrine Pharmaceuticals to Report Fiscal Year 2009 Financial Results

Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine

Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program